James B. Tananbaum bought $2.5M of Latigo Biotherapeutics (LTGO)
Executed Aug 10, disclosed Aug 11, the same day.
Over the 21 trading sessions from the disclosed entry session (Aug 10), the stock returned +31.1% (delay-adjusted); from the execution session (Aug 10), +31.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
James B. Tananbaum (Director) filed 4 Form 4 reports in the trailing twelve months (4 purchases, 0 sales), most often in Alumis Inc. (ALMS). Across 4 priced purchase filings, the average 21-session return was +61.1% from execution and +48.9% from disclosure (delay-adjusted; derived). The largest single filing was $7.0M of ALMS (411,764 sh across 2 lots, as filed), executed Jan 8.
Healthcare · Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→